SARS-CoV-2 501Y. V2 escapes neutralization by South African COVID-19 donor plasma
SARS-CoV-2 501Y.V2 (B.1.351), a novel lineage of coronavirus causing COVID-19, contains
substitutions in two immunodominant domains of the spike protein. Here, we show that …
substitutions in two immunodominant domains of the spike protein. Here, we show that …
The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection
An understanding of how broadly neutralizing activity develops in HIV-1-infected individuals
is needed to guide vaccine design and immunization strategies. Here we used a large …
is needed to guide vaccine design and immunization strategies. Here we used a large …
SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape
Characterizing SARS-CoV-2 evolution in specific geographies may help predict properties
of the variants that come from these regions. We mapped neutralization of a SARS-CoV-2 …
of the variants that come from these regions. We mapped neutralization of a SARS-CoV-2 …
Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants
…, AT DiPiazza, IJ Gordon, SH Hait, T Hermanus… - Science, 2021 - science.org
INTRODUCTION Worldwide appearance of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) variants of concern (VOCs) with increased transmissibility and resistance to …
2 (SARS-CoV-2) variants of concern (VOCs) with increased transmissibility and resistance to …
Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape
Neutralizing antibodies are likely to play a crucial part in a preventative HIV-1 vaccine.
Although efforts to elicit broadly cross-neutralizing (BCN) antibodies by vaccination have been …
Although efforts to elicit broadly cross-neutralizing (BCN) antibodies by vaccination have been …
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim …
…, C Briner, PK Aley, S Bhikha, T Hermanus… - The Lancet …, 2021 - thelancet.com
Background People living with HIV are at an increased risk of fatal outcome when admitted
to hospital for severe COVID-19 compared with HIV-negative individuals. We aimed to …
to hospital for severe COVID-19 compared with HIV-negative individuals. We aimed to …
Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity
…, R Keeton, T Moyo-Gwete, T Hermanus… - Science translational …, 2021 - science.org
SARS-CoV-2 variants that escape neutralization and potentially affect vaccine efficacy have
emerged. T cell responses play a role in protection from reinfection and severe disease, but …
emerged. T cell responses play a role in protection from reinfection and severe disease, but …
Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition
…, LN Carpp, DH Barouch, NN Mkhize, T Hermanus… - Nature Medicine, 2022 - nature.com
The Antibody Mediated Prevention trials showed that the broadly neutralizing antibody (bnAb)
VRC01 prevented acquisition of human immunodeficiency virus-1 (HIV-1) sensitive to …
VRC01 prevented acquisition of human immunodeficiency virus-1 (HIV-1) sensitive to …
Prior infection with SARS-CoV-2 boosts and broadens Ad26. COV2. S immunogenicity in a variant-dependent manner
R Keeton, SI Richardson, T Moyo-Gwete, T Hermanus… - Cell host & …, 2021 - cell.com
The Johnson and Johnson Ad26.COV2.S single-dose vaccine represents an attractive option
for coronavirus disease 2019 (COVID-19) vaccination in countries with limited resources. …
for coronavirus disease 2019 (COVID-19) vaccination in countries with limited resources. …
Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop
The targets of broadly cross-neutralizing (BCN) antibodies are of great interest in the HIV
vaccine field. We have identified a subtype C HIV-1-superinfected individual, CAP256, with high…
vaccine field. We have identified a subtype C HIV-1-superinfected individual, CAP256, with high…